Beam Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 540

Employees

  • Stock Symbol
  • BEAM

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $20.90
  • (As of Friday Closing)

Beam Therapeutics General Information

Description

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Contact Information

Website
www.beamtx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 238 Main Street
  • Cambridge, MA 02142
  • United States
+1 (857)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 238 Main Street
  • Cambridge, MA 02142
  • United States
+1 (857)

Beam Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Beam Therapeutics Stock Performance

As of 20-Nov-2026, Beam Therapeutics’s stock price is $20.90. Its current market cap is $2.16B with 103M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$20.90 $20.94 $20.39 - $38.26 $2.16B 103M 2.05M -$1.01

Beam Therapeutics Financials Summary

As of 30-Sep-2026, Beam Therapeutics has a trailing 12-month revenue of $147M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,619,814 1,889,335 1,289,888 1,375,671
Revenue 146,644 139,743 63,518 377,709
EBITDA (120,769) (101,431) (403,872) (157,825)
Net Income (108,354) (79,992) (376,742) (132,527)
Total Assets 1,269,072 1,481,177 1,103,824 1,459,714
Total Debt 243,872 154,123 161,425 172,689
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Beam Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Beam Therapeutics‘s full profile, request access.

Request a free trial

Beam Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Beam Therapeutics‘s full profile, request access.

Request a free trial

Beam Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based
Drug Discovery
Cambridge, MA
540 As of 2026

Boston, MA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Beam Therapeutics Competitors (127)

One of Beam Therapeutics’s 127 competitors is Verve Therapeutics, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Verve Therapeutics Formerly VC-backed Boston, MA
Prime Medicine Formerly VC-backed Cambridge, MA
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
Editas Medicine Formerly VC-backed Cambridge, MA
Sharp Therapeutics (Biotechnology) Formerly VC-backed Pittsburgh, PA
You’re viewing 5 of 127 competitors. Get the full list »

Beam Therapeutics Patents

Beam Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026192929-A1 Methods and compositions for editing an intronic mutation associated with phenylketonuria (pku) Pending 10-Mar-2025
WO-2026183200-A1 Targeted lipid nanoparticles Pending 26-Feb-2025
WO-2026174164-A1 Nanomaterials comprising triols Pending 14-Feb-2025
WO-2026169723-A1 Lipid nanoparticles, methods of making lipid nanoparticles, and uses thereof Pending 04-Feb-2025
WO-2026161459-A1 Non-genotoxic conditioning methods and compositions Pending 22-Jan-2025 C07K16/2896
To view Beam Therapeutics’s complete patent history, request access »

Beam Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Beam Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Beam Therapeutics‘s full profile, request access.

Request a free trial

Beam Therapeutics Investments & Acquisitions (3)

Beam Therapeutics’s most recent deal was a Merger/Acquisition with Guide Therapeutics for . The deal was made on 23-Feb-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Guide Therapeutics 23-Feb-2021 Merger/Acquisition Drug Delivery
BliNK Therapeutics 01-Sep-2018 Merger/Acquisition Biotechnology
Verve Therapeutics 07-Aug-2018 Early Stage VC Drug Discovery
To view Beam Therapeutics’s complete investments and acquisitions history, request access »

Beam Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

32.65 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Beam Therapeutics’s complete esg history, request access »

Beam Therapeutics Exits (1)

Beam Therapeutics’s most recent exit was on 07-Aug-2018 from Verve Therapeutics. The exit was categorized as with 6 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Verve Therapeutics 07-Aug-2018 Completed
  • 6 buyers
To view Beam Therapeutics’s complete exits history, request access »

Beam Therapeutics FAQs

  • When was Beam Therapeutics founded?

    Beam Therapeutics was founded in 2017.

  • Where is Beam Therapeutics headquartered?

    Beam Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Beam Therapeutics?

    Beam Therapeutics has 540 total employees.

  • What industry is Beam Therapeutics in?

    Beam Therapeutics’s primary industry is Drug Discovery.

  • Is Beam Therapeutics a private or public company?

    Beam Therapeutics is a Public company.

  • What is Beam Therapeutics’s stock symbol?

    The ticker symbol for Beam Therapeutics is BEAM.

  • What is the current stock price of Beam Therapeutics?

    As of 20-Nov-2026 the stock price of Beam Therapeutics is $20.90.

  • What is the current market cap of Beam Therapeutics?

    The current market capitalization of Beam Therapeutics is $2.16B.

  • What is Beam Therapeutics’s current revenue?

    The trailing twelve month revenue for Beam Therapeutics is $147M.

  • Who are Beam Therapeutics’s competitors?

    Verve Therapeutics, Prime Medicine, CRISPR Therapeutics, Editas Medicine, and Sharp Therapeutics (Biotechnology) are some of the 127 competitors of Beam Therapeutics.

  • What is Beam Therapeutics’s annual earnings per share (EPS)?

    Beam Therapeutics’s EPS for 12 months was -$1.01.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process